Evidence map›Paper›PMID 35572626›Full record

ReviewFrontiers in microbiology2022

Insights Into Persistent HIV-1 Infection and Functional Cure: Novel Capabilities and Strategies.

Tram M Ta, Sajjaf Malik, Elizabeth M Anderson, Amber D Jones, Jocelyn Perchik, Maryann Freylikh, Luca Sardo, Zackary A Klase, Taisuke Izumi

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Herbal formulations, Product Nkabinde andFrontiers in pharmacology · 2025
    Article
  12. Article
  13. Review
  14. Current drug discovery technologies · 2025
    Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Tram M TaDepartment of Biological Sciences, Misher College of Arts and Sciences, University of the Sciences in Philadelphia, Philadelphia, PA, United States.
Sajjaf MalikDepartment of Biological Sciences, Misher College of Arts and Sciences, University of the Sciences in Philadelphia, Philadelphia, PA, United States.
Elizabeth M AndersonOffice of the Assistant Secretary for Health, Region 3, U.S. Department of Health and Human Services, Washington, DC, United States.
Amber D JonesDepartment of Biological Sciences, Misher College of Arts and Sciences, University of the Sciences in Philadelphia, Philadelphia, PA, United States.
Jocelyn PerchikDepartment of Biological Sciences, Misher College of Arts and Sciences, University of the Sciences in Philadelphia, Philadelphia, PA, United States.
Maryann FreylikhDepartment of Biological Sciences, Misher College of Arts and Sciences, University of the Sciences in Philadelphia, Philadelphia, PA, United States.
Luca SardoDepartment of Infectious Disease and Vaccines, Merck & Co., Inc., Kenilworth, NJ, United States.
Zackary A KlaseDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA, United States.
Taisuke IzumiDepartment of Biological Sciences, Misher College of Arts and Sciences, University of the Sciences in Philadelphia, Philadelphia, PA, United States.
University of the Sciences · USDrexel University · USMerck & Co., Inc., Rahway, NJ, USA (United States) · USOffice of the Assistant Secretary for Health · US

Funding

Understanding the overlap of chromatin alteration in HIV-1 and drug abuseDP2DA044550 · NIDA · UNIVERSITY OF THE SCIENCES PHILADELPHIA · PI KLASE, ZACHARY ALAN · 2017 to 2017
$2.1M
NIDA NIH HHS DP2 DA044550
6 · The paper itself

Abstract

Although HIV-1 replication can be efficiently suppressed to undetectable levels in peripheral blood by combination antiretroviral therapy (cART), lifelong medication is still required in people living with HIV (PLWH). Life expectancies have been extended by cART, but age-related comorbidities have increased which are associated with heavy physiological and economic burdens on PLWH. The obstacle to a functional HIV cure can be ascribed to the formation of latent reservoir establishment at the time of acute infection that persists during cART. Recent studies suggest that some HIV reservoirs are established in the early acute stages of HIV infection within multiple immune cells that are gradually shaped by various host and viral mechanisms and may undergo clonal expansion. Early cART initiation has been shown to reduce the reservoir size in HIV-infected individuals. Memory CD4+ T cell subsets are regarded as the predominant cellular compartment of the HIV reservoir, but monocytes and derivative macrophages or dendritic cells also play a role in the persistent virus infection. HIV latency is regulated at multiple molecular levels in transcriptional and post-transcriptional processes. Epigenetic regulation of the proviral promoter can profoundly regulate the viral transcription. In addition, transcriptional elongation, RNA splicing, and nuclear export pathways are also involved in maintaining HIV latency. Although most proviruses contain large internal deletions, some defective proviruses may induce immune activation by expressing viral proteins or producing replication-defective viral-like particles. In this review article, we discuss the state of the art on mechanisms of virus persistence in the periphery and tissue and summarize interdisciplinary approaches toward a functional HIV cure, including novel capabilities and strategies to measure and eliminate the infected reservoirs and induce immune control.

Indexed as

Block-and-Lock strategydefective provirusesfunctional HIV cureHIV latencyHIV persistencehuman immunodeficiency virus (HIV)immunotherapykick-and-kill strategy

Identifiers

PMID35572626
PMCPMC9093714
OpenAlexW4224936011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.